Table 1.
Demographic and Clinical Characteristics of Patients
| RLAI group | PP group | p | |
|---|---|---|---|
| Age (years) | 46.4 ± 10.4 | 43.5 ± 11.8 | NS |
| Onset (years) | 29.5 ± 11.9 | 32.9 ± 11.7 | NS |
| Sex (Male/Female) | 7/4 | 4/6 | NS |
| Diagnosis (schizophrenia/schizoaffective disorder) | 11/0 | 9/1 | NS |
| PANSS total score | 83.0 ± 19.9 | 78.1 ± 21.0 | NS |
| DIEPSS total score | 3.1 ± 3.1 | 1.1 ± 1.7 | NS |
| Total antipsychotics dosea | 432 ± 112.6 | 342 ± 94.7 | NS |
| Residence status (solitude/not solitude) | 4/7 | 3/7 | NS |
| Concomitant medication, n (%) | |||
| Anticholinergic drugs | 1 (9) | 0 (0) | NS |
NS no significant difference, RLAI risperidone long-acting injection, PP paliperidone palmitate, PANSS the positive and negative syndrome scale, DIEPSS the drug-induced extrapyramidal symptoms scale
aChlorpromazine-equivalent dose